Novartis ' generics subsidiary, Sandoz, has been withdrawn in the USA because of illegal price-fixing and other antitrust violations to account. The company had accepted a settlement in the amount of $ 195 million, announced the justice Department on Monday in Washington.
The company was accused of Manipulation of tenders and the fixing of prices of patent-free medicines, worth more than $ 500 million between 2013-2015.
to cooperate with The Novartis subsidiary said in a statement that the investigations by the US authorities. The managers of the affair are now employed by the company. (chk/sda)
Created: 03.03.2020, 05:14 PMUpdated Date: 03 March 2020, 05:05